Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29614987 | 1.00 | HSD17B10 (0.54) | HSD17B10TDP1GPR35ALDH1A1TSHR | |
| SCHEMBL29623123 | 0.84 | ALDH1A1 (0.53) | HSD17B10TDP1GPR35ALDH1A1MEN1 | |
| SCHEMBL20187601 | 0.84 | ALDH1A1 (0.53) | HSD17B10TDP1GPR35ALDH1A1MEN1 | |
| SCHEMBL20312266 | 0.83 | HSD17B10 (0.54) | HSD17B10TDP1GPR35ALDH1A1TSHR | |
| SCHEMBL6701294 | 0.82 | TSHR (0.46) | TDP1ALDH1A1TSHRKMT2ASMN1; SMN2 | |
| SCHEMBL29956172 | 0.82 | TDP1 (0.67) | HSD17B10TDP1GPR35ALDH1A1TSHR | |
| SCHEMBL6500391 | 0.82 | TDP1 (0.67) | HSD17B10TDP1GPR35ALDH1A1TSHR | |
| SCHEMBL12480468 | 0.80 | TDP1 (0.48) | HSD17B10TDP1GPR35ALDH1A1TSHR | |
| SCHEMBL22206200 | 0.80 | TDP1 (0.48) | HSD17B10TDP1GPR35ALDH1A1TSHR | |
| SCHEMBL29954306 | 0.80 | TDP1 (0.48) | HSD17B10TDP1GPR35ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1471 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250194617-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-06-19 | — | — | US | claimed |
| US-20250169514-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-05-29 | — | — | US | claimed |
| CN-115745870-B | Ondansetron intermediate of agar Synthesis method of tetrahydrocarbazolone | 常州兰陵制药有限公司 | 2025-02-14 | — | — | CN | claimed |
| US-12188898-B2 | Non-enzymatic electrochemical sensor for measuring analytes | TERUMO KABUSHIKI KAISHA (JP) | 2025-01-07 | — | — | US | claimed |
| WO-2024254448-A2 | BORONATE PRODRUG NANOFORMULATIONS IN DISEASE TREATMENTS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-12-12 | — | — | WO | claimed |
| CN-118878402-A | Preparation method of trifluoromethyl ketone compound based on palladium catalysis of C-N bond cleavage | 大连理工大学 | 2024-11-01 | — | — | CN | claimed |
| CN-118758925-A | Colorimetric indicator displacement sensing array and application thereof in white tea rapid identification | 集美大学 | 2024-10-11 | — | — | CN | claimed |
| EP-2961395-B1 | TARGETED NANOPARTICLES | CALIFORNIA INST OF TECHN (US) | 2024-06-19 | — | — | EP | claimed |
| WO-2024123732-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CANCER | Dantari, Inc. (US) | 2024-06-13 | — | — | WO | claimed |
| CN-116874411-B | Synthesis method of 1-bromocarbazole | 西安欧得光电材料有限公司 | 2024-04-16 | — | — | CN | claimed |
| US-20080200684-A1 | Process for Preparing Ethyl (s)-2-Ethoxy-4-[N-[1-(2-Piperidinophenyl)-3-Methyl-1-Butyl]Aminocarbonyl Methyl]Benzoate and Use Thereof for the Preparation of Repaglinide | ACTAVIS GROUP PTC HF (IS) | 2008-08-21 | — | — | US | claimed |
| WO-2008099286-A2 | IMPROVED PROCESS FOR PREPARING ETHYL (S)-2-ETHOXY-4-[N-[1-(2- PIPERIDINOPHENYL)-3-METHYL-1-BUTYL]AMINOCARBONYL METHYL]BENZOATE AND USE THEREOF FOR THE PREPARATION OF REPAGLINIDE | ACTAVIS GROUP PTC EHF (US) | 2008-08-21 | — | — | WO | claimed |
| EP-1107982-A1 | REVERSIBLE BORONATE COMPLEXES OF 1,2-$i(CIS)-DIOL CYCLIC-PEPTIDES | Eli Lilly & Company (US) | 2001-06-20 | — | — | EP | claimed |
| EP-1009415-A4 | INHIBITORS OF $g(b)-LACTAMASES AND USES THEREFOR | UNIV NORTHWESTERN (US) | 2000-10-25 | — | — | EP | claimed |
| EP-1009415-A1 | INHIBITORS OF $g(b)-LACTAMASES AND USES THEREFOR | NORTHWESTERN UNIVERSITY (US) | 2000-06-21 | — | — | EP | claimed |
| WO-2000012540-A1 | REVERSIBLE BORONATE COMPLEXES OF 1,2-CIS-DIOL CYCLIC-PEPTIDES | ELI LILLY AND COMPANY (US) | 2000-03-09 | — | — | WO | claimed |
| WO-1998056392-A1 | INHIBITORS OF β-LACTAMASES AND USES THEREFOR | NORTHWESTERN UNIVERSITY (US) | 1998-12-17 | — | — | WO | claimed |
| WO-1998054578-A1 | CHEMILUMINESCENT HEMOGLOBIN ASSAY | BIO-RAD LABORATORIES, INC. (US) | 1998-12-03 | — | — | WO | claimed |
| US-5254776-A | Synthesis of bromobiphenyls | MALLINCKRODT SPECIALTY CHEMICALS COMPANY (US) | 1993-10-19 | — | — | US | claimed |
| US-4409391-A | Process to produce anthracycline compounds | HOFFMANN-LA ROCHE INC. (US) | 1983-10-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12188898-B2 | Non-enzymatic electrochemical sensor for measuring analytes | SPR, SRR, BLVRB | HSD17B10 1220/4885TDP1 1967/4885GPR35 2158/4885 |
| US-20080200684-A1 | Process for Preparing Ethyl (s)-2-Ethoxy-4-[N-[1-(2-Piperidinophenyl)-3-Methyl-1-Butyl]Aminocarbonyl Methyl]Benzoate and Use Thereof for the Preparation of Repaglinide | MEP1B, GABRE, BPGM | HSD17B10 2590/4885TDP1 1622/4885GPR35 2683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.